Overview
RNTX market data
Price History
RNTX price chart · 1M
- O
- 0.801900
- H
- 0.811200
- L
- 0.792200
- C
- 0.792200
- Vol
- 3,247.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $0.80
- Previous Close
- $0.80
- Day High
- $0.81
- Day Low
- $0.79
- 52 Week High
- $1.52
- 52 Week Low
- $0.70
- 7 Day Return
- +1.64%
- 30 Day Return
- +3.83%
- 90 Day Return
- -28.63%
- 1 Year Return
- -37.87%
- Daily Notional Volume
- $2.6K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.96 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.36 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 14.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.69 – $2.18 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $67.7M · P/B 1.80.
Company News
FDA Grants Rein Therapeutics Fast Track Designation For LTI-03Benzinga · Aug 20, 2026, 12:02 PM
HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price TargetBenzinga · Aug 18, 2026, 11:36 AM
Rein Therapeutics Q2 EPS $(0.10) Beats $(0.17) EstimateBenzinga · Aug 14, 2026, 10:47 AM
Rein Therapeutics Announces Nature Communications Publication Of First-In-Human LTI-03 Data In 24 IPF Patients, Says Drug Reduced Multiple Fibrosis And Inflammation MarkersBenzinga · Aug 4, 2026, 12:05 PM
Rein Therapeutics Begins Enrolling Patients In Phase 2 RENEW TrialBenzinga · Jul 21, 2026, 12:05 PM
Maxim Group Initiates Coverage On Rein Therapeutics with Buy Rating, Announces Price Target of $4Benzinga · Jul 20, 2026, 6:13 PM
HC Wainwright & Co. Maintains Buy on Rein Therapeutics, Lowers Price Target to $8Benzinga · Jun 1, 2026, 10:42 AM